Engineered Phagocytic Receptor Compositions and Methods of Use Thereof
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application 62/841,190, filed Apr 30, 2019. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,013,764 | Engineered Phagocytic Receptor Compositions and Methods of Use Thereof In force · High confidence UsedRemaining | Create Medicines, Inc. | In force | High confidence | ||
| US 11,026,973 | Engineered Phagocytic Receptor Compositions and Methods of Use Thereof In force · High confidence | Create Medicines, Inc. | In force | High confidence | ||
| Application 17/209,712 | Engineered Phagocytic Receptor Compositions and Methods of Use Thereof Abandoned Abandoned Aug 3, 2026 | Create Medicines, Inc. | Abandoned | Abandoned Aug 3, 2026 | ||
| Application 17/514,828 | Engineered Chimeric Fusion Protein Compositions and Methods of Use Thereof Pending Not granted | Create Medicines, Inc. | Pending | Not granted | ||
| Application 19/553,952 | Targeted LNP Compositions for in Vivo Immune Cell Engineering and Methods of Use Thereof Pending Not granted | CREATE Medicines, Inc. | Pending | Not granted |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Create Medicines, Inc..
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.